ES2172536T3 - Liberacion y movilizacion de celulas hematopoyeticas. - Google Patents

Liberacion y movilizacion de celulas hematopoyeticas.

Info

Publication number
ES2172536T3
ES2172536T3 ES94918421T ES94918421T ES2172536T3 ES 2172536 T3 ES2172536 T3 ES 2172536T3 ES 94918421 T ES94918421 T ES 94918421T ES 94918421 T ES94918421 T ES 94918421T ES 2172536 T3 ES2172536 T3 ES 2172536T3
Authority
ES
Spain
Prior art keywords
pct
1alpha
mobilization
liberation
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94918421T
Other languages
English (en)
Inventor
Michael Berisford Comer
Matthew John Mccourt
Lars Michael Wood
Michael George Hunter
Richard Mark Edwards
Andrew John Hubert Gearing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
British Biotech Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939312343A external-priority patent/GB9312343D0/en
Priority claimed from GB939324252A external-priority patent/GB9324252D0/en
Priority claimed from GB9402188A external-priority patent/GB9402188D0/en
Application filed by British Biotech Pharmaceuticals Ltd filed Critical British Biotech Pharmaceuticals Ltd
Application granted granted Critical
Publication of ES2172536T3 publication Critical patent/ES2172536T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

INHIBIDORES DE CELULAS PRINCIPALES TALES COMO LA PROTEINA-1{AL}(MUMIP-1}AL Y HUMIP-1{AL}/LD78) INFLAMATORIA MACROFAGA HUMANA Y MURINA Y SUS ANALOGOS Y VARIANTES QUE REFUERZAN LA LIBERACION Y MOVILIZACION DE LAS CELULAS HEMATOPOYETICAS. ESTA PROPIEDAD LAS HACE MAS UTILES EN EL REFUERZO DE LAS RESPUESTAS CONTRA INFECCIONES Y EN LA RECOLECCION DE CELULAS.
ES94918421T 1993-06-15 1994-06-15 Liberacion y movilizacion de celulas hematopoyeticas. Expired - Lifetime ES2172536T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939312343A GB9312343D0 (en) 1993-06-15 1993-06-15 Pharmaceutical use
GB939324252A GB9324252D0 (en) 1993-11-25 1993-11-25 Pharmaceutical use
GB9402188A GB9402188D0 (en) 1994-02-04 1994-02-04 Pharmaceutical use

Publications (1)

Publication Number Publication Date
ES2172536T3 true ES2172536T3 (es) 2002-10-01

Family

ID=27266724

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94918421T Expired - Lifetime ES2172536T3 (es) 1993-06-15 1994-06-15 Liberacion y movilizacion de celulas hematopoyeticas.

Country Status (8)

Country Link
US (1) US5925568A (es)
EP (1) EP0703784B1 (es)
JP (1) JPH08511263A (es)
AT (1) ATE213952T1 (es)
AU (1) AU6974294A (es)
DE (1) DE69430059T2 (es)
ES (1) ES2172536T3 (es)
WO (1) WO1994028916A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6447766B1 (en) 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
DE69433301T2 (de) * 1993-06-08 2004-09-09 Smithkline Beecham Corp. Methoden zur erhöhung der biologischen aktivität von chemokinen
US5595973A (en) * 1994-09-12 1997-01-21 Biomeasure Incorporated Protection of hemopoietic cells during chemotherapy or radiotherapy
GB9426012D0 (en) * 1994-12-22 1995-02-22 British Biotech Pharm Mobilisation of haematopoietic cells
US6713052B1 (en) 1995-10-24 2004-03-30 Human Genome Sciences, Inc. Method of mobilizing stem cells with chemokine β-8
GB9600559D0 (en) * 1996-01-11 1996-03-13 British Biotech Pharm Use of chemokines
EP0848012A1 (de) 1996-12-13 1998-06-17 Roche Diagnostics GmbH Verwendung von Polypeptiden zur Behandlung von Thrombozytopenien
US6919318B1 (en) 1998-04-22 2005-07-19 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
DE69929432T2 (de) * 1998-04-22 2006-09-28 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Erhöhung der immunantworten bei genetischer immunisierung durch verwendung eines chemokins
DK1016414T3 (da) 1998-12-17 2005-01-17 Applied Research Systems Humant væksthormon til stimulering af hæmatopoise og immunkonstitution efter transplantation med hæmatopoietiske stamceller i mennesker
EP1016413A1 (en) * 1998-12-30 2000-07-05 Applied Research Systems ARS Holding N.V. Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
US10281478B2 (en) 2000-04-06 2019-05-07 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US9694038B2 (en) 2000-04-06 2017-07-04 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US7361329B2 (en) 2000-04-21 2008-04-22 Chemocentryx, Inc. Compositions for inducing an immune response
AU2002219830A1 (en) * 2000-11-10 2002-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
US20040115175A1 (en) * 2000-11-10 2004-06-17 The Board Of Trustees Of The Leland Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
US7247297B2 (en) * 2001-09-14 2007-07-24 The University Of Chicago Use of DF3/MUC1 regulated expression in gene therapy
WO2003035106A1 (en) * 2001-10-24 2003-05-01 Chemocentryx Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen
JP2004196770A (ja) * 2002-10-24 2004-07-15 Effector Cell Institute Inc 樹状細胞前駆体の血中レベル上昇剤
AU2005326226B2 (en) * 2005-01-31 2010-11-11 Eci, Inc. Immunopotentiating agent
WO2009024426A1 (en) * 2007-07-27 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Immunizing compositions for inducing 'bystander' killing of pathogens
US8846559B2 (en) * 2008-11-03 2014-09-30 Saudi Basic Industries Corporation Stable shape-selective catalyst for aromatic alkylation and methods of using and preparing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809419D0 (en) * 1988-04-21 1988-05-25 Pragnell I Stem cell inhibitors
CA2064558C (en) * 1989-09-25 2001-01-30 Ian B. Pragnell Method for inhibiting growth of stem cells

Also Published As

Publication number Publication date
DE69430059D1 (de) 2002-04-11
JPH08511263A (ja) 1996-11-26
WO1994028916A1 (en) 1994-12-22
ATE213952T1 (de) 2002-03-15
AU6974294A (en) 1995-01-03
EP0703784A1 (en) 1996-04-03
EP0703784B1 (en) 2002-03-06
DE69430059T2 (de) 2002-11-14
US5925568A (en) 1999-07-20

Similar Documents

Publication Publication Date Title
ES2172536T3 (es) Liberacion y movilizacion de celulas hematopoyeticas.
NO20001583D0 (no) Stimulering av hematopoetiske celler in vitro
ZA981936B (en) Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
MX9405383A (es) Imidazo(4,5-c) piridin-4-aminas.
MY120511A (en) New pesticides
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
ES2161279T3 (es) Nucleosidos y nucleotidos que contienen racimos de boro.
ES2162909T3 (es) Composiciones de fosfolipidos silicona modificadas.
ES2177625T3 (es) Citoquina cc-1 humana circulante.
PT967888E (pt) Composicao edulcorane soluvel contendo fibras alimentares e sua utilizacao
ATE228760T1 (de) Thrombininhibitoren
FR2776188B1 (fr) Oleamide de glycylglycine en dermo-cosmetologie
DK0793503T3 (da) Anvendelse af hepatocyt-vækstfaktor til inducering af profilerering og differentiering af hemotopoietiske celler
ATE366763T1 (de) Lagerstabile polyisocyanate
KR950701812A (ko) 렌티바이러스-유도된 질환의 치료에 유용한 생물학적으로 활성인 우레이도 유도체(Biologically active ureido dervatives useful in the treatment of lentivirus-induced sisease)
ES2196802T3 (es) Lactatos de citronelilo y/o de dihidrocitronelilo, su preparacion y su utilizacion.
ES2158441T3 (es) Arilheterociclos con actividad herbicida.
DK289388D0 (da) Desinfektionsmiddel til at desinficere hud og overflader paa genstande
RU95114125A (ru) Ингибитор пролиферации стволовых кроветворных клеток
AU1402495A (en) Use of macrophage depleting agents for prolonging the survival of non-autologus hematopoietic cell transplants and animal model assay systems
ES2116574T3 (es) 4-guanidinobutiramida para mejorar la circulacion de la sangre.
ES2141923T3 (es) Uso hipocolesterolemico, antiaterosclerotico e hipotrigliceridemico de derivados aminoacetilmercapto.
DK0958290T3 (da) 1,4-Dihydropyridinderivater og terapeutisk anvendelse heraf
TR200103748T2 (tr) Organ nakli reddinin inhibe edilmesi için UK 114 proteinin kullanımı
UA43383C2 (uk) Штам синьо-зелених водоростей spirulina platensis - продуцент біологічно активних речовин з антибластомними та антимікробними властивостями

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 703784

Country of ref document: ES